| |
Move beyond a single set of forecast numbers and embrace uncertainty in healthcare forecasting: IQVIA’s Forecast Horizon is enabling pharma to broaden their analysis and drive deeper insights. Learn more.
|
|
Today's Big NewsOct 4, 2022 |
| By Gabrielle Masson Bristol Myers Squibb is partnering up with San Francisco biotech SyntheX to ride into the lawless land of molecular glue degrader discovery—all while giving the biotech the potential to pocket up to $550 million in biobucks. |
|
|
|
By Angus Liu Pfizer’s Talzenna has been holding onto a breast cancer nod while three other marketed peers battle it out in ovarian cancer. But with a pivotal trial win, the PARP inhibitor outlier is joining the fight in a more competitive tumor type—and Pfizer is already talking about blockbuster sales. |
By Conor Hale The continuous glucose monitoring system is now available in the U.K., Ireland, Germany, Austria and Hong Kong. |
By Annie Burky CommonSpirit Health is managing an IT security incident affecting some of its facilities in multiple regions including Nebraska, Tennessee and Washington state. The number of facilities affected is still undisclosed as is the security of patient data following the incident which reportedly began Monday. |
By Gabrielle Masson The U.S. government has granted Vir Biotechnology a multi-year contract and the chance to make up to $1 billion in efforts to respond to public health emergencies and prepare for future pandemics prompted by the flu or other infectious diseases. |
By Fraiser Kansteiner After an indefinite commercial delay on its Shire-acquired rare disease drug this spring, Takeda’s yearslong Natpara manufacturing saga is drawing to a close. |
By Zoey Becker In a patent infringement case that's been ongoing since 2017, a U.S. District Court upheld a jury's original ruling in favor of Daiichi Sankyo. Novartis will have to shell out $177.8 million and give the company 9% royalties on melanoma therapy Tafinlar until a key patent expires. |
By Conor Hale The compact DASH system, developed in part by researchers at Northwestern University’s Feinberg School of Medicine, aims to deliver results within 15 minutes. |
By Nick Paul Taylor Pfizer has delivered a split decision on Voyager Therapeutics’ capsids. After spending one year assessing the capsids, the Big Pharma has paid $10 million to take up its option to use the gene therapy technology against a rare neurological disease target but backed out of the cardiovascular part of the deal. |
By Kevin Dunleavy Amid reports that AstraZeneca's Evusheld is ineffective against the latest subvariant of omicron, BA.4.6, the FDA has updated its fact sheet for the antibody combo. The agency now says the product can increase the risk of COVID-19 infection for variants that it does not neutralize. |
By Frank Diamond Studies have yet to capture how racial and ethnic minorities fare in MA compared to traditional Medicare, according to a new KFF literature review. |
By Conor Hale The company’s Medical Imaging Suite will also serve as a gateway for the development of AI programs for quickly parsing patient scans. |
By Max Bayer With the $11.6 billion sale to Pfizer officially behind it, Biohaven is directing clinical aspirations toward its epilepsy program. But to chart a new path, it will need to shake off consecutive late-stage losses. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk with many of the Fierce 15 honorees to find out what makes them unique. We also share highlights from the Fierce Biotech Summit on gene editing innovations and battling biotech's bear market. |
|
|---|
|
|
|
Monday, October 17, 2022 | 11am ET / 8am PT Join the Omic Revolution! Register now to attend a FREE webinar to leverage deep multiomic data integration for target and biomarker discovery.
|
|
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| WhitepaperLearn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
| Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
| Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
